Amendia Spin-Off Completes First Round of Financing

Marietta Ga.-based Vivex Biomedical Inc., a biomaterials manufacturer, has successfully completed its first round of private equity financing. The financing involved an over-subscribed offering of the company’s preferred stock, generating $7.6 million in start-up capital.

“We are grateful to our shareholders and investors,” said Tracy Anderson, president and CEO of Vivex. “They have provided us capital to grow our rapidly expanding biosciences portfolio while allowing the executive team to focus on the strategic execution and day to day operations. We are excited about the future of Vivex.”

According to the company, start-up capital will be used to refine current and develop new products, expand its team, and identify and pursue strategic partnerships and other opportunities. The company’s patented flagship products, currently in development, include the Miami stem cell and mimetic pattern implants and other protected intellectual property. Vivex’s core biomaterials include demineralized bone matrix, sponge, allograft, and calcium phosphate products backed by a proprietary cleansing process that sustains bioactivity.

Vivex was founded this year in a spin-off from Amendia Inc. a spinal implant manufacturer.